vitamin B3 · nicotinic acid · nicotinamide · flush niacin
500 mg · vegan · gluten-free · 100 caps
Affiliate link · we earn from qualifying purchases. No paid placements.
Niacin (vitamin B3, nicotinic acid) is an essential water-soluble vitamin that at pharmacological doses (1–3 g) produces dramatic lipid-modifying effects: it raises HDL by 20–35%, lowers LDL by 10–25%, and reduces triglycerides by 20–50%. It is the most effective agent for raising HDL available.
Niacin inhibits hepatic diacylglycerol acyltransferase-2 (DGAT2), reducing VLDL secretion and subsequent LDL formation. It also stimulates ApoA-I synthesis, increasing HDL production, and activates GPR109A receptors on adipocytes, reducing free fatty acid release.
Adults with low HDL and high triglycerides who cannot tolerate statins, individuals with familial dyslipidemia, those with elevated Lp(a) (niacin is one of few agents that lowers it).
People with active liver disease, gout (niacin raises uric acid), diabetes (may worsen glycemic control), pregnant or breastfeeding women, history of peptic ulcer disease.
Pick a depth — minimum to maximal coverage
No full stack configured.
Click individual supplement pills above to buy each on Amazon India.
✓ Evening dosing reduces flushing severity; take with low-fat snack
✓ Food reduces flushing and GI discomfort; avoid hot beverages around dosing
Niacin inhibits hepatic diacylglycerol acyltransferase-2 (DGAT2), reducing VLDL secretion and subsequent LDL formation.
Each bar = one cited trial. Effect varies by methodology, dose, and population.
Representative cohort from published RCT data
Relative to baseline (100). Data from published clinical literature.
see study
→ NULL: Niacin + simvastatin did NOT reduce cardiovascular events vs simvastatin alone (N=3,414, 3 years)
see study
→ NULL + HARM: Niacin + laropiprant did NOT reduce events; increased diabetes complications, infections, bleeding (N=25,673)
see study
→ CDP follow-up: niacin reduced all-cause mortality by 11% vs placebo at 15 years (N=1,119)
C · Powerful lipid-modifying effects confirmed; two major modern trials NULL for outcomes; pre-statin era data positive; regulatory withdrawals in Europe; niche role in statin-intolerant patients
A plain-English read of the literature behind this supplement. Not a clinical recommendation.
Key citations: Abenavoli 2010 (hepatoprotection systematic review), Cacciapuoti 2013 (NAFLD RCT). richResearch section contains study filters.
How to use Niacin specifically for low HDL — the right dose, timing, blood markers to track, and how to know if it is working.
A clinical evidence review of Niacin — RCT data, effect sizes, evidence grade, and what the numbers mean for your specific situation.
Everything you need to know about Niacin — mechanism, dose, safety, buying guide for India, and what the research actually says.
SacredBod's longer take on Niacin — context the structured blocks above don't capture.
Niacin is the most controversial supplement in the lipid-lowering landscape. It produces the most dramatic HDL elevation of any available agent—raising levels by 20–35%—while simultaneously lowering LDL and triglycerides. These are not marginal effects; they are substantial, dose-dependent, and reproducible. Yet two of the largest cardiovascular outcome trials in history found that adding niacin to statin therapy produced no benefit and, in one case, actual harm. This disconnect between biomarker improvement and clinical outcomes defines the niacin debate.
The AIM-HIGH trial (2011, New England Journal of Medicine, PMID 22085343) was the first major blow. Investigators randomized 3,414 patients with established cardiovascular disease, low HDL, and high triglycerides to extended-release niacin (1,500–2,000 mg) plus simvastatin or simvastatin alone. Niacin raised HDL by 25% and lowered triglycerides by 30%—exactly as expected. Yet the primary endpoint (cardiovascular events) was identical between groups. The trial was stopped early for futility. The honest interpretation: in patients already receiving intensive statin therapy, niacin’s lipid-modifying effects do not translate to additional event reduction.
HPS2-THRIVE (2014, New England Journal of Medicine, PMID 25014686) was even more damning. This massive trial randomized 25,673 high-risk patients to extended-release niacin plus laropiprant (an anti-flushing agent) or placebo, all on background statin therapy. Not only was there no cardiovascular benefit, but the niacin group experienced significantly more diabetes complications, serious infections, and bleeding episodes. The European Medicines Agency subsequently withdrew niacin-laropiprant combinations from the market. The FDA added warnings about increased risk of diabetes and infection. Niacin went from standard-of-care to clinical pariah in three years.
The pre-statin era data provides important context. The Coronary Drug Project (CDP, 1975) randomized 8,341 men to niacin or placebo before statins existed. Niacin reduced non-fatal MI by 27% and, in a 15-year follow-up (Canner et al., 1986, PMID 3520295), reduced all-cause mortality by 11%. These are real benefits—but they occurred in an era without statins. The modern null results suggest that statins capture most of the benefit that niacin can provide, leaving no incremental advantage. The honest framing: niacin is a powerful lipid modifier with genuine effects, but its role in modern cardiology is limited to niche populations—statin-intolerant patients, severe hypertriglyceridemia, or elevated Lp(a)—where other options are inadequate.
Peptides are physician-only. Tell us a bit and we'll route you to the right specialist.
